Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$0.00$0.00— vs Q1 2021 Net Income-$98.91K-$98.91KN/M vs Q1 2021 EPS Diluted$0.00$0.00— vs Q1 2021 Operating Income-$93,500N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Mar 31, 2022 · filed May 13, 2022 · 43 d after period end